Our analysis shows higher PSMB9 expression levels in uLMS compared to the benign tumor, LM, and normal adjacent myometrium, MM groups (Figure 1a), but no difference was observed at the protein level (Figure 1b) nor in gynecological cell lines (uterine leiomyosarcoma, endometrial/uterine cancer, and vulvar/ovarian leiomyosarcoma cell lines) (Figure 1c). This evidence concerns the gene PSMB9 and ovary leiomyosarcoma.